---
figid: PMC8616345__cancers-13-05724-g004
figtitle: Advances in Immunotherapy and the TGFB Resistance Pathway in Metastatic
  Bladder Cancer
organisms:
- Homo sapiens
- Mus musculus
pmcid: PMC8616345
filename: cancers-13-05724-g004.jpg
figlink: /pmc/articles/PMC8616345/figure/cancers-13-05724-f004/
number: F4
caption: Current TGF-β signaling inhibitors being used in combination with ICI for
  human clinical trials (adapted from “TGF-β signaling”, by BioRender.com (2021).
  Retrieved from https://app.biorender.com/biorender-templates, accessed on 14 October
  2021).
papertitle: Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic
  Bladder Cancer.
reftext: David J. Benjamin, et al. Cancers (Basel). 2021 Nov;13(22):5724.
year: '2021'
doi: 10.3390/cancers13225724
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: urothelial carcinoma | bladder cancer | immunotherapy | TGF-β resistance
  pathway
automl_pathway: 0.9113591
figid_alias: PMC8616345__F4
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC8616345__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8616345__cancers-13-05724-g004.html
  '@type': Dataset
  description: Current TGF-β signaling inhibitors being used in combination with ICI
    for human clinical trials (adapted from “TGF-β signaling”, by BioRender.com (2021).
    Retrieved from https://app.biorender.com/biorender-templates, accessed on 14 October
    2021).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFB1
  - TGFB2
  - TGFB3
  - SMAD7
  - SMURF2
  - SMAD4
  - SMAD2
  - SMAD3
  - TF
  - Tgfb1
  - Ltbp1
  - Smad7
  - Smurf2
  - Smad4
  - Smad2
  - Smad3
---
